CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Pharmaceutical Intermediates Velpatasvir API Velpatasvir Powder Velpatasvir1
Pharmaceutical IntermediateVelpatasvirVelpatasvir Powder
Xi'an Qiushi Co., Ltd.
Preview:
Product DescriptionPharmaceutical Intermediates Velpatasvir API Velpatasvir Powder VelpatasvirProduct DescriptionProduct DetialsProduct NameVelpatasvirApperanceWhite powderCAS1377049 - 84 - 7MFC49H54N8O8MW883.00velpatasvir is a new type of pan-genotypic hepatitis C drug developed by Gilead Sciences. It is a composite tablet composed of the NS5B inhibitor sofibuvir and the NS5A inhibitor velpatasvir (VEL), taken orally once a day. In June and July 2016, the FDA of the United States and the European Union successively approved Epclusa for the treatment of adult patients infected with hepatitis C virus types 1 to 6. It can be used alone for patients without cirrhosis or compensated cirrhosis, or in combination with ribavirin for the treatment of patients with decompensated cirrhosis.Application&FunctionViparatavir is a second-generation NS5A inhibitor and has good antiviral activity in vitro against all genotypes of HCV as well as common NS5A mutations and drug resistance mutations. After oral administration of viparatvir, the Tmax of viparatvir was 3 hours. Compared with taking it on an empty stomach, consuming standard meals and high-fat foods can prolong the peak time of viperativir by 34% and 21% respectively, and the plasma protein binding rate of viperativir after entering the bloodstream exceeds 99.5%. Viparatavir is mainly metabolized by CYP2B6, CYP2C8 and CYP3A4, and 77% is excreted through bile.SpecificationCertificate of Analysis
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...